HomeTTNP • NASDAQ
Follow
Titan Pharmaceuticals, Inc. common stock
Previous close
$6.97
Day range
$7.10 - $7.26
Year range
$5.00 - $16.60
Market cap
6.63M USD
Avg Volume
11.42K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 0.00 | -100.00% |
Operating expense | 1.44M | 12.02% |
Net income | -1.97M | 23.23% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.93M | 24.86% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 6.76M | 130.17% |
Total assets | 8.09M | 99.26% |
Total liabilities | 1.44M | -46.42% |
Total equity | 6.64M | — |
Shares outstanding | 914.23K | — |
Price to book | 0.82 | — |
Return on assets | -53.39% | — |
Return on capital | -60.58% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -1.97M | 23.23% |
Cash from operations | -2.25M | -42.24% |
Cash from investing | 504.00K | — |
Cash from financing | 406.00K | — |
Net change in cash | -1.34M | 15.39% |
Free cash flow | -1.01M | 3.61% |
About
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Founded
1992
Headquarters
Website
Employees
4
